Cue Biopharma, Inc. (CUE)

Cue Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	7.02	5.49	1.25	14.94	3.15	3.46
Revenue Growth (YoY)	1525.00%	340.96%	-91.67%	373.68%	-8.79%	202.67%
Gross Profit	7.02	5.49	1.25	14.94	3.15	3.46
Selling, General & Admin	16.69	16.68	16.17	17.31	14.65	12.74
Research & Development	41.61	40.8	38.58	41.35	33.55	27.49
Other Operating Expenses	0.16	0.16	-0.28	0	0	0
Operating Expenses	58.46	57.64	54.47	58.65	48.2	40.23
Operating Income	-51.44	-52.15	-53.23	-43.71	-45.04	-36.77
Interest Expense / Income	1.27	1.25	0.71	0	0	0
Other Expense / Income	-2.73	-2.66	-0.93	-0.05	-0.46	-0.48
Pretax Income	-49.97	-50.73	-53.01	-43.67	-44.58	-36.29
Income Tax	0	0	0	0.5	0.21	0.41
Net Income	-49.97	-50.73	-53.01	-44.16	-44.78	-36.7
Shares Outstanding (Basic)	49	46	36	31	29	22
Shares Outstanding (Diluted)	49	46	36	31	29	22
Shares Change	10.78%	28.35%	13.95%	9.05%	30.16%	9.48%
EPS (Basic)	-1.07	-1.11	-1.49	-1.41	-1.56	-1.66
EPS (Diluted)	-1.07	-1.11	-1.49	-1.41	-1.56	-1.66
Free Cash Flow	-38.97	-39.96	-41.97	-39.73	-33.09	-30.72
Free Cash Flow Per Share	-0.79	-0.87	-1.18	-1.27	-1.15	-1.39
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-732.71%	-949.89%	-4275.10%	-292.56%	-1427.96%	-1063.21%
Profit Margin	-711.84%	-924.10%	-4257.83%	-295.56%	-1419.79%	-1061.18%
Free Cash Flow Margin	-555.09%	-727.85%	-3371.16%	-265.90%	-1049.01%	-888.17%
EBITDA	-44.6	-46.05	-50.49	-42.41	-43.52	-35.48
EBITDA Margin	-635.28%	-838.83%	-4055.50%	-283.83%	-1379.73%	-1025.80%
Depreciation & Amortization	4.11	3.44	1.81	1.26	1.06	0.81
EBIT	-48.71	-49.49	-52.3	-43.67	-44.58	-36.29
EBIT Margin	-693.80%	-901.42%	-4200.56%	-292.25%	-1413.26%	-1049.25%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).